drugset / Trial / NCT02311946

A Pilot Study To Investigate The Effect Of Concurrent Antacid Administration On The Bioavailability Of Six Experimental Formulations Of Palbociclib

NCT02311946

Phase 1 Completed 60 enrolled Pfizer
Non-randomizedCrossoverOpen-labelBasic science

Summary

This study will investigate whether concurrent administration of rabeprazole, an antacid known as a proton pump inhibitor, alters the absorption of the drug palbociclib when given as one of six experimental formulations.

Timeline

Start
2015-01
Primary completion
2015-04
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Palbociclib Small molecule 125 mg Oral
Subject Rabeprazole Small molecule 40 mg Oral

Indications

No indication recorded.